{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038049","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.160719+00:00","generated_at":"2026-06-09T14:22:00.862700+00:00","sec_items":["1.01","2.03","3.02","7.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ensysce Biosciences raises $1.7M in convertible note and warrant private placement","bullets":["Aggregate investment of $1.7M through senior secured convertible notes and warrants; initial close of $566,667 on or before Oct 26.","Notes convertible at $1.5675 per share, bear 6% interest, 6-month maturity, 8% original issue discount.","Warrants to purchase up to 1,255,697 shares at $1.5675 exercisable for 5 years; second close of $1,133,333 upon SEC registration effectiveness.","Proceeds to fund clinical development of TAAP and MPAR platforms, including time-of-onset study for PF614.","Obligation to begin monthly principal and interest payments in cash or stock at holder's election after 90 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038049","json":"https://secwatch.observer/filing/0001493152-23-038049.json","markdown":"https://secwatch.observer/filing/0001493152-23-038049.md","text":"https://secwatch.observer/filing/0001493152-23-038049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/0001493152-23-038049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T14:22:00.862700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2af85e08b1eb9647c227644175c5546ad7c55f42","claim":"Ensysce Biosciences, Inc. incurred senior notes of aggregate principal amount of $612,000 with investors at 6.0% per annum maturing six months from their respective date of issuance.","evidence_excerpt":"the Company will issue to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $612,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/0001493152-23-038049-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"aggregate principal amount of $612,000"},{"label":"Counterparty","value":"investors"},{"label":"Rate","value":"6.0% per annum"},{"label":"Maturity","value":"six months from their respective date of issuance"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"9c607cbb6ead5de7ee98137fc25260e795b970fb","claim":"Ensysce Biosciences, Inc. entered into Securities Purchase Agreement with investors valued at $1.7 million (effective 2023-10-23).","evidence_excerpt":"On October 23, 2023, Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) entered into a Securities Purchase Agreement (the “SPA”) for an aggregate financing of $1.7 million with investors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/0001493152-23-038049-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"investors"},{"label":"Value","value":"$1.7 million"},{"label":"Effective","value":"2023-10-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}